Cytokinetics
Developer of muscle-directed medicines led by MYQORZO for hypertrophic cardiomyopathy.
Something off on this page? Send us feedback.
Profile
Develops and commercializes muscle-directed medicines, led by MYQORZO for obstructive hypertrophic cardiomyopathy, while advancing cardiac myosin drugs for other forms of hypertrophic cardiomyopathy and heart failure. Revenue now comes chiefly from its first commercial product, with additional programs dependent on clinical and regulatory outcomes.
Develops and commercializes small-molecule medicines that alter muscle contractility, centered on a specialty cardiology franchise. MYQORZO (aficamten), an oral cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy, is launched in the United States and Germany; wider international access combines direct launches with regional partners. Pairs in-house muscle-biology research with a targeted sales model focused on specialist cardiologists and treatment centers.
Extends aficamten into non-obstructive and pediatric hypertrophic cardiomyopathy while advancing omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for a hypercontractile form of preserved-ejection-fraction heart failure. CK-089 keeps an early neuromuscular program in the portfolio. Product revenue currently depends on MYQORZO adoption, reimbursement, and required safety monitoring, while further growth depends on regulatory review and clinical-trial outcomes.
Company facts
Key statistics
Year to date +16.8% · Average volume (30d) 1.8M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Barclays | Reiterate | Overweight | $87 | $110 | |
| Aug 10, 2026 | Truist Financial | Target | $106 | $112 | ||
| Aug 7, 2026 | Needham | Reiterate | Buy | $84 | $112 | |
| Aug 7, 2026 | RBC Capital | Reiterate | Outperform | $117 | $112 | |
| Jul 7, 2026 | RBC Capital | Reiterate | Outperform | $119 | $117 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$1.63 | −$1.50 | +8.0% | $17.6M | $28.6M | +62.7% | −5.67% |
| May 5, 2026Q1 FY26 | −$1.67 | −$1.67 | 0.0% | $8.5M | $19.4M | +127.2% | −2.92% |
| Feb 24, 2026Q4 FY25 | −$1.48 | −$1.50 | −1.4% | $6.9M | $17.8M | +156.3% | −10.29% |
| Nov 5, 2025Q3 FY25 | −$1.59 | −$1.54 | +3.1% | $8.0M | $1.9M | −75.9% | +1.88% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $66.8M | $1.9M | $17.8M | $19.4M | $31.9M | |
| Gross profit | −$98.3M | $64.5M | −$743.0K | $14.9M | $17.0M | $29.2M | |
| Operating income | −$155.6M | −$111.5M | −$166.8M | −$178.4M | −$183.6M | −$175.9M | |
| Net income | −$161.4M | −$134.4M | −$306.2M | −$183.0M | −$206.0M | −$198.8M | |
| Diluted EPS | −$1.36 | −$1.12 | −$2.55 | −$1.50 | −$1.67 | −$1.50 | |
| Gross margin | -6,223.1% | 96.6% | -38.4% | 83.9% | 87.6% | 91.4% | |
| Operating margin | -9,856.3% | -167.0% | -8,613.4% | -1,004.6% | -948.7% | -551.1% |
Fiscal years (4-quarter sums)FY21 $70.4M · FY22 $94.6M · FY23 $7.5M · FY24 $18.5M · FY25 $88.0M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.17B · Total debt $1.27B · Total assets $1.92B · Shareholders' equity −$173.5M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 124.43M · Float 119.24M · 95.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 20.09M | 16.15% | 13F | Aug 7, 2026 |
| T. Rowe Price Investment Management, Inc. | 18.72M | 15.04% | 13F | Aug 14, 2026 |
| Wellington Management Group LLP | 6.93M | 5.57% | 13F | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 6.71M | 5.39% | 13F | Aug 13, 2026 |
| State Street Corp | 6.49M | 5.22% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Fady Ibraham Malik | officer: EVP Research & Development | −3,500 | $75.82 |
| Aug 10, 2026 | Robert I. Blum | director, officer: President & CEO | −7,500 | $76.76 |
| Jul 30, 2026 | Andrew Callos | officer: EVP, Chief Commercial Officer | −14,000 | $79.88 |
| Jul 27, 2026 | Robert I. Blum | director, officer: President & CEO | −7,500 | $80.87 |
| Jul 21, 2026 | Fady Ibraham Malik | officer: EVP Research & Development | −3,500 | $80.59 |
Peers
- Bristol-Myers Squibb
Only approved cardiac myosin inhibitor in oHCM; Camzyos at $1.1B 2025 revenue.
- Edgewise Therapeutics
Cardiac sarcomere modulator EDG-7500 in Phase 2 for both oHCM and nHCM.
- Novartis (ADR)
Entresto (sacubitril/valsartan), the dominant ARNI standard of care in HFrEF.
- AstraZeneca (ADR)
Farxiga (dapagliflozin), SGLT2 inhibitor approved for HFrEF and HFpEF.
- Eli Lilly
Jardiance (empagliflozin), SGLT2 leader approved for HFrEF and HFpEF.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cytokinetics | $72.50 | +0.54% | $8.97B | — | — | 126.4 | −57.1% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Edgewise Therapeutics | $42.76 | −0.04% | $4.60B | — | — | — | — |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Median | 23.8 | 15.8 | 4.7 | +6.1% |